P-228: ASCT does not benefit patients who are MRD negative following induction therapy: updated results from the Phase 2 Cardamon study
Kwee Yong(CRUK Lung Cancer Centre of Excellence), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Jonathan Sive(University College London Hospitals NHS Foundation Trust), James D. Cavenagh(National Health Service), Tushhar Dadaga(Cancer Research UK), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), William W. Wilson(Dakota State University), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Elizabeth Philips, Selina J Chavda(University College London), Reuben Benjamin(King's College London), María Cuadrado(University College London), Michael Chapman(Dartmouth College)
Cited by 0
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605